Physician profile
Robert Heifetz
NPI 1629538434
$366.67
in general payments reported to CMS, 2019-2025
11 companies · $97.43 in 2025
The $97.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $67.50 · 2024: $202 · 2025: $97.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $64.08 | 2025 | Freestyle Libre 2 |
| Abbvie INC. | $54.35 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $49.99 | 2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $33.45 | 2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $31.27 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $30.88 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $29.94 | 2023-2024 | Evenity, Prolia, Repatha |
| Phathom Pharmaceuticals, INC. | $21.36 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $18.11 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $17.53 | 2024 | |
| Pfizer INC. | $15.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Heifetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.